Key result
Continuation of oral anticoagulation therapy after atrial fibrillation ablation was associated with a 2.2% incidence of thromboembolic events compared to 1% with discontinuation (P=0.145).
Why the study?
Does oral anticoagulation therapy continuation prevent thromboembolic events in patients treated with transcatheter ablation for atrial fibrillation?
Cohort (n=766)
Does oral anticoagulation therapy continuation prevent thromboembolic events in patients treated with transcatheter ablation for atrial fibrillation?
Absolute Event Rate: 2.2% vs 1%
p-value: p=0.145
In patients undergoing AF ablation, thromboembolic event rates are low regardless of OAT maintenance, but OAT continuation is associated with hemorrhagic events, highlighting the need for risk stratification using CHA2DS2-VASc scores.
No takes yet. Share an insight, caveat, or question.
Thromboembolic rates remain low after AF ablation irrespective of OAT status; observational data leave open optimal duration and support CHA2DS2-VASc-guided decisions.
Gaita et al. (2014) conducted a cohort in Atrial fibrillation (n=766). Oral anticoagulation therapy continuation vs. Oral anticoagulation therapy discontinuation was evaluated on Thromboembolic events (p=0.145). Continuation of oral anticoagulation therapy after atrial fibrillation ablation was associated with a 2.2% incidence of thromboembolic events compared to 1% with discontinuation (P=0.145).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: